Folkman's Legacy of Bold and Creative Thinking Endures
During the course of a 74-year life cut short by his sudden death in 2008, Folkman changed the world repeatedly with bold ideas that ranged from implantable pacemakers and subcutaneous birth control to an entirely new field of medical study: how diseases like cancer recruit blood vessels from the body via angiogenesis.
Novel Clinical Trial "Graduates" Two Promising Agents
The first results from the I-SPY 2 trial, which is evaluating novel agents in the neoadjuvant treatment of breast cancer, show encouraging possibilities for veliparib (ABT-888) and neratinib (PB272).
New Paradigms Emerge for Translating Immunotherapy Into Broad Clinical Use
Although breakthrough successes are generating a renaissance for anticancer immunotherapies, the framework for translating promising research results into clinical practice remains very much under construction.
Ibrutinib Represents "Transformative" Approach in CLL Treatment
Jennifer R. Brown, MD, PhD, and John Byrd, MD, are leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
Study Supports First-Line Eribulin Therapy in Metastatic Breast Cancer
Eribulin mesylate (Halaven) proved safe and effective as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer in final phase II clinical trial results
ILI Provides Valuable Option for Inoperable Melanoma Metastases
As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.
Success of First BTK Inhibitor Opens New Options in B-Cell Malignancies
A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.
Discovery Dilemma: Narrow "Superiority" Standard Is an Inferior Way to Evaluate Novel Therapies
The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.
Minimally Invasive Techniques Make Strides in Liver Surgery
During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures
Dendritic Vaccine Improves Survival in Recurrent Glioblastoma
A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments
PARP Inhibitor BMN 673 Advances in Breast Cancer Study
As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.
Taking the Next Step
The big story in oncology research for the past several years has been the emergence of immunotherapy as a viable strategy for attacking many different tumor types.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512